Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its investigational drug HDM1002. This small molecule is a complete agonist of the GLP-1 receptor with oral activity, known for its strong efficacy and high selectivity.
HDM1002: A Potential Game-Changer in Diabetes Treatment
HDM1002 is capable of strongly activating the GLP-1 receptor, which in turn induces the production of cyclic adenosine monophosphate (cAMP). This activation has been associated with significant effects on improving glucose tolerance, lowering blood sugar levels, and promoting weight loss, all while demonstrating good safety. The drug’s potential to address multiple diabetes-related health concerns positions it as a promising candidate in the field of diabetes treatment. HDM1002 filed for clinical trials in China in February and in the US in April, marking a significant step towards global development.
Huadong Medicine’s Diversified Diabetes Pipeline
Huadong Medicine is recognized for its differentiated diabetes product pipeline, which includes a range of inhibitors such as α-Glycosidase, DPP-4, SGLT-2, and GLP-1 receptor agonists. The addition of HDM1002 to this pipeline further strengthens the company’s commitment to innovation in diabetes care and underscores its efforts to provide patients with a variety of treatment options.-Fineline Info & Tech
